| October 23, 2014 | ISSUE NUMBER 374 VOL 4 |
|
Healthcare Reform
Obamacare Rx Usage Revealed
The 2015 Obamacare Exchange Rx insurance offerings will be presented to patients on November 15th. But what insights do American Rx brand managers and marketers actually have on the results of the Obamacare Rx experience in 2014? Very little, until this month, when the New York Times detailed its first six months as reported by two pharmacy benefit managers. Tom Norton discusses highlights ...Read more
E-Book: Celebrating 50 Years of DIA
This commemorative e-book includes special articles, as well as DIA session highlights and news that pharmaceutical and clinical trial professionals will find important and informative.  Download Today
Regulatory
CDER's New "Super Office" to Promote Drug Quality
The DHSS and the White House have finally signed off on her plan to establish a new CDER “super” Office of Pharmaceutical Quality (OPQ), a change originally proposed in thefall of 2012. Jill Wechsler reports ...Read more
IP
New Patent-Defense Path for Pharma
Just over three years ago, the America Invents Act introduced litigation procedure to challenge the validity of patent claims. The response by patent challengers has been overwhelming. But the majority—more than 86%—of the petitions have challenged electrical and mechanical patents, while petitions challenging pharmaceutical and biotech patents account for just over 5%. David Dalke looks into the disparity ...Read more
Covance MarketPlace. Connect Right from the Start.
Find the right partner with the desire and resources to help you realize your molecule’s potential. Through our private, secure and exclusive online portal, you can share information about your molecule to potential investors or partners. It's one more innovative way to transform the profile and success of your program, delivered by the only global drug development partner with expertise spanning preclinical, clinical and commercial phases.  Learn more
Global
The Baltic States: A Growing Clinical Research Market
The Baltic States approve around 80 new clinical trial applications per country each year, falling mainly within the therapeutic areas of oncology, neurology/psychiatry, and endocrinology. States legislation is harmonized and the regulatory process is similar to other EU countries. The timelines are also attractive—the approval process takes approximately 60 days. Donatas Grina, Indre Tutlyte, Audrius Sveikata look at these and other factors that make the region an attractive location for clinical trials
...Read more
Improving Lab Efficiency Through New Mobility and Data Visualization Techniques
Wednesday, October 29, 2014 10:00 AM Eastern Daylight Time
To Register Free at:  www.pharmexec.com/labefficiency
|
|
|
|
 //aTyr Pharma (San Diego, CA and Hong Kong) announced today that rare disease expert John C. McKew, Ph.D., has joined the company as Vice President, Research.//The Board of Directors of Cytori Therapeutics (San Diego, CA) announced that Lloyd H. Dean has tendered his resignation as a member of the Board, effective November 1, 2014.//Cubist Pharmaceuticals (Lexington, MA) announced that its Board of Directors selected Robert J. Perez as Chief Executive Officer, effective January 1, 2015. Perez, who currently serves as Cubist’s President and Chief Operating Officer, will succeed Michael W. Bonney, who is retiring from his current role as CEO on December 31, 2014. Bonney will become non-executive Chair of Cubist’s Board of Directors.// |
|
|
|
|
|
 |
|
|
 |
|
 |
Slow growth in developed economies or a slowdown in high growth markets: which concerns you the most?
|
|
|
|
